Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Hepatitis C Virus – Epidemiology – Middle East & Africa Data

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of hepatitis c virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of HCV for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s HCV forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with HCV per year?
  • How will improvements in survival change the number of people living with HCV?
  • Of all people with HCV, how many in each country have been formally diagnosed?
  • Of all people diagnosed with HCV, how many in each country are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HCV over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts 49 HCV patient populations, including the following:

  • Diagnosed GT3 viremic noncirrhotic prevalent cases.
  • Viremic cirrhotic prevalent cases.
  • Drug-treated GT3 viremic noncirrhotic sustained virologic response (SVR) events.
  • Drug-treated GT2 viremic cirrhotic events.
  • Viremic noncirrhotic prevalent cases.
  • Diagnosed GT2 viremic cirrhotic prevalent cases.
  • GT3 viremic prevalent cases.
  • Drug-treated GT4+ viremic noncirrhotic events.
  • Drug-treated GT3 viremic cirrhotic SVR events.
  • Drug-treated GT1 viremic noncirrhotic events.
  • … and many more (details available on request).

Note: Coverage may vary by country.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east